Most Admired Pharma & BioTech Visionaries, Shaping the Industry's Future - 2024

VOL 02I ISSUE 04 I 2024 From Lab to Market Strategies for Successful Commercializa?on in the Biotech Industry Bioinforma?cs and Big Data Unleashing the Poten?al for Advancements in Pharma Research Michael Kurr Global Head of Human Pharma MOST Services ADMIRED Boehringer PHARMA & Ingelheim International BIOTECH GmbH VISIONARIES, SHAPING THE INDUSTRY'S FUTURE - 2024 From Concept to Reality From Concept to Reality Michael Michael Building Internal Service Organizations for Excellence in Customer Experience

Biotech is the art of Turning Nature's Code into Cures, a Symphony of Science Playing the Melody of Progress.

n the background of the pharmaceutical and The decisions made by healthcare leaders in the biotechnology industries, healthcare leaders play a Pharma and Biotech sector have far-reaching I pivotal role in steering organizations towards implications on global health. These leaders contribute Leadership in success. These leaders not only navigate the complex to the development of therapies that address unmet and ever-evolving regulatory environment but also medical needs, tackle infectious diseases, and improve drive innovation, ensure patient-centric approaches, overall public health. Their strategic decisions impact and contribute significantly to global health outcomes. the availability and affordability of medicines Promoting Integrity Hire worldwide. Healthcare leaders in the Pharma and Biotech sector face a myriad of regulatory challenges due to the Healthcare leaders in the Pharma and Biotech sector stringent oversight governing drug development and are the driving force behind advancements that shape and Responsibility commercialization. They must possess a deep character. the future of healthcare. Their ability to navigate Editor’s Note understanding of global regulatory frameworks, regulatory complexities, drive innovation, adopt anticipate changes, and implement strategies to ensure patient-centric approaches, impact global health, compliance. Effective leaders contribute to the timely establish collaborations, and uphold ethical and approval of drugs, facilitating their entry into the sustainable practices underscores their profound market and ultimately benefiting patients. significance. The Pharma and Biotech sector thrives on innovation, Spotlighting the journey of these personalities, be it in drug discovery, development, or manufacturing CIOLook features the inspiring stories of Most Train skill. processes. Healthcare leaders play a critical role in Admired Pharma & BioTech Visionaries, Shaping the fostering a culture of innovation within their Industry's Future – 2024. These leaders continue to organizations. They encourage research and address challenges and embrace opportunities; they development initiatives, invest in cutting-edge contribute significantly to the betterment of human technologies, and forge collaborations with academia health on a global scale. and other industry players to bring groundbreaking therapies to the market. Flip through the pages and indulge in the stories that showcase profound excellence and spark inspiration. The ultimate goal of healthcare leaders is to improve patient outcomes. Leaders in the Pharma and Biotech Have a delightful read! sector are instrumental in shaping patient-centric approaches throughout the entire product lifecycle. This includes understanding patient needs, incorporating real-world evidence into decision- making, and ensuring accessibility and affordability of innovative treatments. Anish Miller..

C O From Concept to Reality From Concept to Reality 08 V E Michael Michael R S Building Internal Service Organizations Building Internal Service Organizations T for Excellence in Customer Experience for Excellence in Customer Experience O C O N T E N T S R PROFILE Y Michaele Armstrong 22 Bridging Bioscience Innovation and Impact From Lab to Market Strategies for Successful Commercializa?on in the 18 Biotech Industry Bioinforma?cs and Big Data Unleashing the Poten?al for 26 A R T I C L E S Advancements in Pharma Research

Pooja M Bansal Editor-in-Chief CONTENT FOLLOW US ON Deputy Editor Anish Miller www.facebook.com/ciolook Managing Editor Katherine Debora www.twi?er.com/ciolook WE ARE ALSO AVAILABLE ON DESIGN Visualizer Dave Bates Art & Design Director Davis Mar?n CONTACT US ON Associate Designer Jameson Carl Featured Person Company Name Brief Email info@ciolook.com SALES Anthony’s role is to build and manage a network of strategic Anthony Cahill Kyzentree For Subscrip?on partnerships across global markets. Senior Sales Manager Wilson T., Hunter D. CEO & Founder kyzentree.com www.ciolook.com Customer Success Manager David Stewart Copyright © 2024CIOLOOK, All Sales Execu?vesTim, Smith rights reserved. The content and Behtash has collaborated with a range of stakeholder groups to Behtash Bahador CISCRP images used in this magazine establish and implement patient- and public-centric initiatives Director, Health ciscrp.org should not be reproduced or across the life-cycle of drug and treatment development. Literacy TECHNICAL transmitted in any form or by any means, electronic, mechanical, Technical Head Peter Hayden photocopying, recording or Boehringer Ingelheim Michael Kurr Technical Consultant Victor Collins otherwise, without prior permission Michael's leadership goes beyond business cases, transforming International GmbH Global Head of Human from CIOLOOK. concepts into tangible realities with real human impact. boehringer-ingelheim.com Reprint rights remain solely with Pharma Services SME-SMO CIOLOOK. Research Analyst Eric Smith With 15 years of hands-on experience in bench and clinical Michaele Armstrong SP3NW SEO Execu?ve Alen Spencer oncology research, Michaele brings a profound understanding Co-founder and sp3nw.org of the field. Associate Director Peter Kelly Peter hold a significant expertise in Sustainability, Recycling, Sales@ciolook.com Pharmafilter Environmental Market Complexity & Value Chain and Pharmafilter B.V B.V. Chief Biobased Economy: Biofuels, Biodegradable Plastics, pharmafilterltd.com February, 2024 Commercial Officer Materials and Green Chemicals. (CCO)

From Concept to Reality From Concept to Reality Michael Michael Building Internal Service Organizations Building Internal Service Organizations Michael Kurr Global Head of Human for Excellence in Customer Experience for Excellence in Customer Experience Pharma Services Boehringer Ingelheim International GmbH Value is the thing you need to show to all of them, and it will need to be a different story wherever you show up.

ichael Kurr leads Boehringer Ingelheim's that can be reinvested in other areas. Observing innovation and transformation as the Global how this reinvestment accelerates the company's go to The right mix of M Head of Human Pharma Services. With over market strategies, ultimately aiding more patients, is two decades of corporate transformation experience, profoundly rewarding. people, a clear Michael has been a pivotal figure in shaping the success stories of renowned organizations like Boehringer In the context of pharmaceutical services, what do mission and Ingelheim, Novartis, Roche Diagnostics, Daimler, and you believe are the key factors for ensuring Schott, as manager and leader or consultant. operational excellence, especially in areas such as vision as well as content operations and customer experience? a culture of Michael's journey is marked by his expertise in building organizations from the ground up, creating teams that To address this question, I'll use the framework of helping each redefine industry standards. His leadership goes beyond people, process and technology, to ensuring operational business cases, transforming concepts into tangible excellence: other through all realities with real human impact. It revolves around motivating and nurturing his teams, with a focus on People: Get the right people who enjoy getting things the rough times individual growth and collective achievement. done. Operations are the core, contributing to business success by implementing strategies and improving makes all the Let's explore the transformative power of leadership, customer engagement. Internal communication is difference. innovation and a relentless commitment to improving the crucial for recognition and career paths. way organizations operate! Process: Large-scale service organizations must have In your role as the Global Head of Human Pharma process design, process management and continuous Services, what aspects of your work bring you the improvement as part of their genetic program. The most fulfilment and what motivates you to continue focus is on reengineering global delivery processes, driving innovation and excellence within the optimizing make versus buy decisions and leveraging pharmaceutical services landscape? different service delivery locations. A deep understanding and cross-functional expertise in There are many things that keep me going, but if I had to processes are crucial for the organization's existence. select three, those would be the following: Over the Instead of the renowned ´structure follows strategy´ the past two decades, I've had the privilege of supporting full equation needs to be 'structure follows process major organizations like Boehringer Ingelheim, follows strategy' to emphasize the role of processes in Novartis, Roche Diagnostics, Daimler, and Schott. creating value. While structure is important, it's the Witnessing these giants evolve and embrace change, process that enables operational excellence and the even reaching a point where some are starting to dance, best customer experience. is profoundly inspiring. I'm particularly motivated by my team, some of whom I've known for many years. Guiding Technology: Automation is a key responsibility. their growth and seeing them thrive is incredibly Understanding technology and its application for global fulfilling. service delivery processes as well as their impact on the business is essential. Bridging the gap between Building new organizations from the ground up and business and IT is critical for success, enabling creating teams that didn't exist before is an efficiency and optimizing resource utilization across unbelievable experience. Witnessing a business case functions. materialize into real human beings, forming genuine teams and accomplishing meaningful work is truly Can you share a pivotal moment in your career that special. Moreover, experiencing the gratitude of those significantly influenced your leadership style and how who find purpose and joy in the roles I've helped them it shaped your approach to leading teams in disruptive secure adds an exceptional dimension to leadership. and ambiguous situations? What brings me deep satisfaction is the measurable Throughout my career, I've encountered different impact—the liberation of resources, be it time or money, managers, with very different leadership styles, some more inspirational than others. Reflecting on these,

I consider several key leadership traits essential especially in disruptive and transformative environments. These traits guide my expectations for myself and others. You need to find your Transparency: My strong focus on output and efficiency sometimes tend to clash with corporate dynamics. I allies in all markets value transparency and dislike speculating on others' motives. As a leader, I prioritize clear communication and work with them with my team, fostering trust, especially in uncertain environments. Many former colleagues joined me at through all kinds of Boehringer Ingelheim, likely due to this transparent leadership approach. challenges. Respect: Respect is often conveyed through communication style, making it a key aspect of leadership. I once left a job in the past due to a continuous lack of respectful communication, emphasizing its importance to me. them, even if it involves extensive travel, is essential. Transformation is never smooth, and at Boehringer Empowerment: I avoid micromanaging and allow my Ingelheim, I found these pioneers in emerging markets teams to make decisions, but it comes with who laid the foundation for a successful global services accountability and trust. Empowerment is a give-and- organization. take based on trust— one can't be empowered without trust. Demonstrating the value of the transformation is equally important but challenging, as stakeholders Fairness: For me, this is one of the most important perceive value differently. Addressing the 'what's in it things in life in general, not only in leadership. Fairness for me' question is key, regardless of mandates. is key, no matter what. Understanding colleagues' perspectives, having open Vision: You need to have a vision as it goes beyond dialogues, while ensuring air cover and sponsorship having just a strategy or a plan. It involves knowing your from the top is critical. destination, your North Star, especially when tasked with transforming the current operating model without In the context of an organization like Human Pharma a clear picture of the new model. Services, maintaining support from the top is mission critical. Unlike traditional service organizations like the The vision remains constant, but the strategy and the typical GBS (Global Business Services), that are not tactical plans may change. Effective leadership involves disputed anymore in large organizations, service sharing a compelling vision that inspires others to organizations like HPS are still a strategic choice and follow. require an ongoing commitment to thrive. In your extensive experience leading teams through As someone passionate about creating and evolving digital transformation, what strategies have you found organizations, can you discuss a specific instance most effective in ensuring a smooth transition and where you built a team from scratch, outlining the maximizing the benefits of digital initiatives within a challenges faced and the successful outcomes large organization? achieved? In a global organization, identifying willing pioneers is Together with my team, we built and continue to evolve crucial for a successful transformation. These are the entire Global Human Pharma Services (HPS) colleagues eager to make a difference, explore new Organization that I am currently heading in paths and adapt quickly. Building relationships with

recently established Medical Affairs Services, which Global Service Layer Organization setup. The colleagues share knowledge and light- is our fastest-growing team focusing on Medical hearted content, including pictures and stories, with Publication support and Medical Writing. Ÿ A team of eight corporate colleagues co-located in each other, thus growing into a team with a strong markets across the globe. sense of belonging, as they manage challenging Digital Content Factory Ÿ Connects the colleagues in the business with the scenarios by lending their colleagues a hand. global services organization including the offshore Ÿ Large-scale offshore digital production outsourced operations and the Delivery Unit. As a leader, what do you consider your most to a global partner in India. Ÿ Makes sure that the global model is working in significant achievement in terms of talent Ÿ Producing emails, edetails (i.e., visual aid slide context of the local realities without compromising development within your teams? Can you share a decks), websites, and banners worldwide for on the economies of scale. success story where you nurtured a team member's Boehringer Ingelheim. potential, leading to exceptional results? Leading a global, cross-functional team often requires Creative Factory (Launched in 2023) effective communication. How do you ensure clear I joined Boehringer Ingelheim in 2019 to lead a small communication and collaboration among team team called the Delivery Unit. Early on, we established Ÿ Operated by the same offshore partner as the members spread across different regions and a direct link to the Corporate Center and drafted plans Digital Factory to ensure seamless and consistent functions? to expand the scale. support end to end i.e., from basic creative work down to production and deployment. In most of our early days, we were a purely virtual In the global services business, scale is key and hence Ÿ Focuses on below-the-line creative work, organization with all the new colleagues joining without we need to grow to be successful and to deliver full emphasizing reutilization, omnichannel deployment, ever having seen anyone in Boehringer Ingelheim value. We professionalized our approach, measured localization, and worldwide leverage of existing personally. This was and is still a challenge we are customer satisfaction, and capitalized on the location's assets. continuously working on. advantages, leading to remarkable development. Now the team has expanded tenfold with a diverse range of digital services supporting global markets. The Global Services Operations Team Crossing all time zones globally and forming a strong, team's spirit is thriving, and all the early team members multicultural team that can deliver and sustain the Ÿ A team that globally oversees all end-to-end, cross- required change to implement this global agenda have evolved into inspiring leaders accountable for functional service delivery processes. requires passion and commitment from everybody significant global delivery teams. The value created, Ÿ Manages global production partners to handle involved. When I started my journey in Boehringer knowledge amassed, and rapid growth fills me with forecasting, reporting, data processing, and Ingelheim, I was privileged enough to hand-select pride. Boehringer Ingelheim. This team delivers services to all financials. almost my entire team. Getting the right people on the markets worldwide. Ÿ Co-located in the Delivery Unit, ensuring smooth bus is probably the first and most important step in The pharmaceutical industry is heavily regulated. operations behind the scenes. such a transformational effort. How do you balance the need for innovation and Since I joined back in 2019, we have built it throughout agility with the necessary compliance and regulatory the last four years from scratch. It has been at full As a team, we meet once a week virtually to share and requirements, ensuring that your digital initiatives geographical scale for two years now, as we grow, learn together, which means that some of us need to get meet industry standards? mature, and professionalize ourselves and the on the call very early, and others need to dial in late environment around us continuously. According to a evening. This poses a challenge to personal life, but our Whatever we do, we do it in full compliance with few external benchmarking studies, we have built one teams are agile in working around the situation, regulations and guidelines. Having said that, what you of the leading content supply chains in the industry. ensuring personal and relationship health at work and experience every now and then during such a home. We also try to get into the rhythm of meeting in transformational journey is that 'Compliance' is almost As we are operating at Currently, my organization consists of five main pillars: person once or twice a year, where we get to know each used as an argument to avoid change. In my view, it is global scale, every Global Services Delivery Unit (owned by Boehringer other well. These days spent together are a real imperative for service team members to be familiar improvement, even Ingelheim) highlight for the entire team. with the compliance rules and ask the famous 'why' small ones make a question a lot. significant difference Ÿ A centralized delivery hub, supporting colleagues What we all share is a passion to build something new, to the overall value we worldwide with Digital Support Operations. to navigate uncharted territory and to deliver And regularly, you will find out that there are ways to Ÿ Services include Campaign Execution and create daily. transformation for the better. And to stay close as a achieve our goals in a compliant and efficient manner. Automation, Webinar Enablement, Content and team, we use many different channels. This means that you need to find your allies in all Digital Asset Management, Search Engine markets and work with them through these kinds of Optimization and Marketing, Data Visualization, Of course, email is still important, but MS Teams is challenges, given the diversity in regulations and norms, Digital Analytics, Learning, Training, and our allowing for a rich team experience even in a virtual which requires local team support.

Being a global internal services provider, we also have Structural Approach an opportunity to make solutions for these challenges an inherent part of our offering. What do I mean by Ÿ Invest in a 'Service Layer Organization' team, that is that? For example, the content approval process close to the markets. (known as the MLR (Medical Legal Regulatory) process Ÿ Close to the business and aware of local realities. in the pharmaceutical industry) provides a huge Ÿ Crucial for making the global model work in the opportunity to be optimized through smart service markets. offerings, offshore support, and automation. Lastly, considering your diverse skill set, which We are also exploring the world of modular content to professional accomplishment are you most proud of generate custom content at a scale. Without and how has it influenced your perspective on challenging the traditional ways of looking at this leadership and the future of pharmaceutical services? regulatory environment, nothing of what the industry is envisioning currently is going to happen. This approval My career spans diverse industries, enabling solutions bottleneck is one example of the hurdles that we need to numerous challenges and accomplishing project to remove by managing it in a smarter way. This is a milestones over the past 20+ years in academia, huge opportunity for teams like mine. consulting, and presently in the pharmaceutical sector. Can you provide insights into your approach to client As career highlights, I would name transforming the relations in the pharmaceutical sector? What operating model of entire sales teams in automotive, strategies have you found most effective in building introducing cross-site business process ownership long-lasting relationships with clients and models in diagnostics, strategically aligning and stakeholders? reengineering R&D departments, as well as establishing global services organizations in corporate As an internal services organization, my clients are pharmaceutical contexts. colleagues aiming to enhance customer experience and support patients. Key points for building such an My passion is to focus on creating meaningful change organization: that improves organizations, emphasizing the importance of leadership, empowerment, and Create Value by understanding various perspectives delegation. As a global leader in the pharmaceutical industry, I've learned that true leadership involves Ÿ Consider the perspectives of colleagues from empowering others and enabling them to deliver. different functions and backgrounds. Ÿ Offer support while ensuring value for all Looking ahead, global service organizations will be stakeholders. crucial in navigating unprecedented changes brought Ÿ Answer the ´what´s in it for me´ question. by advanced analytics, AI, and quantum computing. Agile working and adapting to new technologies quickly Listen Actively and Adapt will be key for survival and competitive advantage. Lastly, I recommend following three basic management Ÿ Actively listen to local nuances and incorporate rules: feedback. Ÿ Balance corporate strategy with on-the-ground 1. Avoid assumptions, as reality always looks realities. different, Ÿ Factor in local requirements to prevent resistance. 2. Be patient and strategic in corporate environments, don´t react immediately and Be Present Onsite and Build Relationships 3. Stay up-to-date and stay relevant by embracing change proactively - cannibalize yourself, otherwise Ÿ Spend time onsite to understand local contexts. someone else will. Ÿ Make friends across the organization for support. Ÿ Travel and engage to implement effective change.

From Lab to Market Strategies for Successful Commercialization in the Biotech Industry he biotech industry is characterized by groundbreaking innovations and scientific advancements that have the T potential to revolutionize healthcare and various other sectors. However, successfully transitioning from the laboratory to the market involves navigating a complex landscape of regulatory requirements, market dynamics, and competitive pressures. This article explores key strategies for achieving successful commercialization in the dynamic and highly specialized field of biotechnology. Strategic Planning and Market Research Identify Market Needs: Before commercializing a biotech product, it's crucial to identify unmet needs within the market. Understand the challenges faced by end-users, healthcare providers, or other stakeholders, and ensure that your product addresses these needs effectively. Comprehensive Market Research: Conduct thorough market research to assess the competitive landscape, target demographics, and potential market size. Understanding the market dynamics enables biotech companies to tailor their commercialization strategies to specific needs and opportunities. Early Engagement with Regulatory Agencies Navigating Regulatory Pathways: The biotech industry is heavily regulated, and early engagement with regulatory agencies is essential. Work closely with regulatory bodies to understand the approval process, address potential roadblocks, and ensure compliance with evolving regulatory standards. Strategic Regulatory Affairs Team: Assemble a skilled regulatory affairs team to guide the product through the regulatory process. Their expertise is crucial in preparing regulatory submissions, interacting with regulatory authorities, and ensuring that the product meets all safety and efficacy requirements. Intellectual Property Protection Patent Strategy: Establish a robust intellectual property (IP) strategy to protect your biotech innovation. Patents provide a 18 19 www.ciolook.com | February 2024 | www.ciolook.com | February 2024 |

competitive advantage by granting exclusive rights, commercialization plan based on real-time feedback allowing companies to recoup investments and and market dynamics. The ability to pivot and innovate maintain a stronghold in the market. in response to changing circumstances is a key determinant of success. Regular IP Audits: Conduct regular IP audits to ensure that your patents remain relevant and enforceable. Investor Relations and Funding Strategies Evaluate the competitive landscape and consider filing additional patents or amendments to strengthen your Effective Investor Communication: Establish IP portfolio. transparent and effective communication with investors. Regularly update them on milestones, Collaborations and Partnerships progress, and challenges. Building strong investor relations is crucial for securing funding and maintaining Strategic Alliances: Form strategic alliances and trust. collaborations with academic institutions, research organizations, or industry partners. These partnerships Diversified Funding Sources: Diversify funding sources can provide access to complementary expertise, to reduce dependency on a single investor or funding resources, and a broader network, accelerating the stream. Explore partnerships, government grants, and development and commercialization process. venture capital to secure the financial resources needed for successful commercialization. Licensing Agreements: Explore licensing agreements with established companies to leverage their Post-Market Surveillance and Feedback Loop distribution networks, market presence, and regulatory experience. Licensing can be a strategic move to Continuous Monitoring and Improvement: Implement expedite market entry and share the risks and costs robust post-market surveillance mechanisms to associated with commercialization. monitor product performance, safety, and user satisfaction. Use the data collected to make continuous Value Proposition and Market Positioning improvements, address emerging issues, and stay ahead of evolving market expectations. Define Clear Value Proposition: Clearly articulate the unique value proposition of your biotech product. Feedback Loop Integration: Establish a seamless Understand how it differentiates from existing feedback loop that incorporates insights from solutions and communicate its benefits to both healthcare providers, end-users, and other healthcare professionals and end-users. stakeholders. This iterative process ensures that the product remains aligned with market needs and fosters Strategic Market Positioning: Develop a strategic a culture of continuous improvement. market positioning plan based on the target market segments. Consider factors such as pricing, Conclusion reimbursement strategies, and marketing approaches to create a compelling narrative that resonates with Successfully commercializing biotech innovations stakeholders. requires a multifaceted approach that combines scientific excellence with strategic business acumen. Flexible Commercialization Models From early engagement with regulatory agencies to the implementation of flexible commercialization models, Adapt to Market Changes: The biotech industry is biotech companies must navigate a complex journey dynamic, with market conditions evolving rapidly. from the laboratory to the market. By incorporating Adopt flexible commercialization models that allow for these key strategies, biotech enterprises can increase adaptability to changes in reimbursement policies, their chances of bringing groundbreaking solutions to market demands, and emerging technologies. the market, ultimately contributing to advancements in healthcare and beyond. Agile Business Strategies: Embrace agile business strategies that enable quick adjustments to the 20 www.ciolook.com | February 2024 |

he vibrant bioscience landscape of the customer discovery, market analysis, and financial Northwest is a thriving ecosystem nurtured by forecasting. T the insightful contributions of Michaele Armstrong. This Co-founder and Associate Director of In the bioscience sector, merging scientific rigor with SP3NW is the architect of growth in this dynamic practical business acumen is essential. My background realm. With a passion for cultivating the potential of life in basic science and pre-clinical research revealed the science startups, she actively shapes the bioscience critical balance needed in translating bioscience landscape through innovative ecosystem development. innovation into practice. Managing timelines, forming strategic partnerships, ensuring reproducibility, Michaele is a small business owner, seasoned addressing adverse events, navigating model variations, entrepreneur advisor, and advocate for the bioscience understanding regulatory constraints, and managing community. She is a driving force behind a costs/funding are challenges that must align with groundbreaking life science business incubator. desired outcomes. Fostering an innovative culture Additionally, as a founding partner of a life science while appreciating commercialization practicalities is innovation cluster, her influence ripples across the pivotal for successfully transitioning bioscience industry. discoveries from the lab to the clinic and into practical application. However, Michaele's journey is not confined to executive functions. With 15 years of hands-on Establishing relationships between academia and experience in bench and clinical oncology research, she industry is crucial in bioscience. How do you navigate brings a profound understanding of the field. Her the complexities of these partnerships, ensuring both extensive research portfolio, boasting 30+ peer- parties benefit and innovative technologies are reviewed publications, stands as an example of her effectively commercialized? commitment to advancing bioscience. Effective industry-academic partnerships are pivotal Let's delve into Michaele's narrative—one of growth, for product development and workforce skill innovation and a relentless pursuit of improved health enhancement. Maximizing the benefits for both sides through bioscience excellence! requires acknowledging the unique capabilities and limitations of each organization. You have an extensive background in both bench and clinical oncology research. How has your hands-on Recognizing the disparities in timelines, often Michaele Armstrong, PhD, MBA experience in research influenced your approach to stemming from funding and regulatory differences, is Co-founder and Associate Director fostering growth in the bioscience industry, crucial. While academic experts aim for the societal SP3NW particularly with startups? impact of their technologies, their incentives may not align with commercialization. To bridge this gap, clear I leverage my research experiences from the University communication, mutual understanding of goals and of Pittsburgh and UPMC, emphasizing the significance internal processes along with synchronized timelines of data-backed, application-oriented solutions. become paramount. Recognizing the iterative nature of progress, I apply the scientific method—forming hypotheses, testing The key lies in aligning interests and establishing assumptions and modifying strategies based on facilitated pathways for the smooth transition of outcomes. This approach isn't limited to science; it innovative technologies from research labs to extends to business formation, product development, commercial applications. This may involve retaining the 22 23 www.ciolook.com | February 2024 | www.ciolook.com | February 2024 |

technical expert's involvement through advisory roles Additionally, our Student Consultant program pairs a Furthermore, we advocate for our startups' attendance or sponsored research, ensuring a cohesive and 1099 consultant with startups for a specific 3-month at pitch events to forge relationships, cultivate best supportive partnership between academia and project. Offering personalized mentorship, industry practices and gain insights into innovative products and industry. workshops, curated referrals, and access to WSU's services. Our monthly CEO luncheons serve as a specialized research facilities, our incubator provides platform for peer mentoring allowing startups to In your role, you've co-founded a life science business comprehensive support for life science startups. absorb emerging trends and technologies strategically. incubator and an innovation cluster. What guiding Evolving from a life science focus to an industry- Through a dynamic and forward-thinking approach, we principles do you believe are essential for creating a agnostic and membership-based approach, SP3NW ensure that the startups we support are well-equipped nurturing environment for startups to thrive, both tailors resources to address each startup's distinct to harness the potential of emerging trends and from a business and a scientific perspective? challenges fostering a solid foundation for success in technologies in the bioscience sector. the specialized bioscience field. Dr. Glenn Prestwich and I launched SP3NW, Communication is key in guiding startups. How do you atmosphere, I aim to empower my team to bridge the Washington State University's business incubator in Being involved in technology transfer and effectively communicate complex scientific concepts gap between scientific prowess and business December 2020. After securing an EDA SPRINT grant commercialization, what challenges do you often to potential investors or partners, ensuring they grasp pragmatism, fostering a cohesive unit that excels in to expand the incubator capabilities and grow the encounter in bridging the gap between scientific the potential impact of these innovations? both realms. network, I was pleased to partner with Katrina Rogers innovation and commercial viability? How do you and Stacia Rasmussen in developing and serving as an overcome these challenges? Effective communication of complex scientific concepts Given your experience, what advice would you give to inaugural board member for the Evergreen Bioscience to investors or partners is a fusion of clarity, relatability aspiring entrepreneurs in the bioscience industry, Innovation Cluster. The challenges in bridging the gap between scientific and tangible vision. I've found that simplifying intricate particularly those aiming to translate innovative ideas innovation and commercial viability often involve scientific ideas without compromising accuracy is into successful and sustainable businesses? The guiding principles for creating a nurturing accurately assessing the market, value proposition, pivotal. I use clear language, complemented by visuals environment revolve around fostering innovation, aligning timelines, managing expectations, and and relatable analogies illustrating the real-world The bioscience industry faces a high failure rate for mitigating risks. collaboration and a supportive culture. In places like implications of these innovations. startups, often due to common causes. For early-stage eastern Washington, these collaborative partnerships founders, understanding these pitfalls is crucial: are frequent and productive because of the trust Open communication, proactive collaboration and a Each audience has its unique perspective so tailoring relationships and ecosystem mindset. phased approach to technology transfer are key. We the message to resonate with their interests and Ÿ Funding Challenges: Lack of funds often indicates navigate these challenges in cooperation with the objectives is essential. By emphasizing the societal operational issues rather than solely financial The ecosystem of industry, academic, economic university's technology transfer office to optimize the benefits and commercial potential of these innovations, scarcity. development, investor, and entrepreneurial partners commercialization process of university IP. I aim to create a compelling narrative that bridges the Ÿ Market Dynamics: Differentiating between the provides resources that address scientific and business gap between scientific depth and practical impact customer and user is vital in recognizing market needs. Encouraging an entrepreneurial spirit, For faculty-driven startups, finding experienced inspiring confidence and understanding among relationships. promoting interdisciplinary collaboration and business partners can be a challenge in aligning early- investors and partners. Ÿ Advisory Support: Building a seasoned advisor maintaining a focus on long-term sustainability are the stage technologies with market viability—an aspect network to fill skill gaps is pivotal embracing their pillars of our incubator, innovation cluster and we're consistently addressing. As a leader, what approach do you take to mentor and feedback is essential. ecosystem. guide your team, particularly in an industry that Ÿ Critical Points of Failure: Identifying and swiftly Bioscience is a rapidly evolving field. How do you stay demands both scientific expertise and business mitigating flaws in science, leadership, or cash SP3NW supports the launch of businesses by ahead of emerging trends and technologies, ensuring acumen? strategies is vital. providing various resources. What unique strategies that the startups you work with are always at the Ÿ Minimal Viable Product (MVP): Recognize your have you employed to ensure these resources are forefront of innovation? My leadership approach revolves around servant MVP and revenue avenues that sustain future tailored to the specific needs of bioscience startups, leadership principles, centered on nurturing the growth development. considering the intricate nature of the industry? Thriving in the field of bioscience demands a and well-being of my team. Open dialogue and Ÿ Resource Utilization: Utilize available resources commitment to continuous learning. This involves providing avenues for skill enhancement are such as trade associations, SBIR/STTR support and In navigating the complexities of the bioscience regular interactions with industry experts, active fundamental. I foster a collaborative culture that incubators/accelerators effectively. For instance, industry, we've tailored support strategies for participation in conferences and fostering a culture of encourages interdisciplinary cooperation and the Health Sciences and Services Authority (HSSA) enhanced clarity. Our distinctive paid Executive curiosity within our organization. We actively continuous learning. in Spokane County offers substantial SBIR/STTR Advisor program aligns an experienced startup collaborate with our State Department of Commerce matching funds. executive, well-versed in fundraising and successful Export Representative. Our startup founders In an industry requiring a blend of scientific excellence exits with a current incubator startup founder. This 5- frequently embark on trade missions abroad, seeking and business astuteness, I recognize the importance of Success in bioscience entrepreneurship requires a month collaboration acknowledges the founder's skill knowledge about technological advancements. creating an environment where individuals can blend of scientific excellence, business acumen, passion gaps without requiring early equity relinquishment leverage their strengths while developing proficiency in for impactful innovation, and at times, serendipity. Be ensuring a dedicated and vetted advisor. complementary domains. By championing a supportive resilient, remain grateful and strive for a positive impact. 24 25 www.ciolook.com | February 2024 | www.ciolook.com | February 2024 |

Bioinformatics and Big Data Unleashing the Potential for Advancements in Pharma Research he pharmaceutical industry stands at the allowing pharmaceutical companies to focus their forefront of scientific innovation, continually efforts on molecules with a higher probability of T striving to unlock the mysteries of diseases and success. develop novel treatments. In recent years, the convergence of bioinformatics and big data has Accelerating Drug Discovery with Big Data emerged as a powerful catalyst, propelling advancements in pharmaceutical research. This article Data Integration and Mining: Big data analytics enable explores the transformative potential of harnessing the integration of diverse datasets, including genomics, bioinformatics and big data to revolutionize drug proteomics, and clinical data. This comprehensive discovery, enhance personalized medicine, and approach facilitates the identification of biomarkers, accelerate the pace of scientific breakthroughs. disease pathways, and potential drug candidates, expediting the drug discovery process. Bioinformatics: A Gateway to Precision Medicine Machine Learning in Drug Discovery: Machine learning Genomic Sequencing: Bioinformatics plays a pivotal algorithms analyze large datasets to identify patterns role in the analysis of vast genomic datasets. The ability and correlations, aiding in predicting drug interactions, to sequence and analyze the entire human genome has optimizing compound structures, and uncovering novel opened avenues for identifying genetic variations, therapeutic avenues. This data-driven approach understanding disease mechanisms, and tailoring enhances the efficiency and success rates of drug treatments based on individual genetic profiles. discovery initiatives. Target Identification and Validation: Leveraging Personalized Medicine and Targeted Therapies bioinformatics tools, researchers can sift through extensive biological data to identify potential drug Patient Stratification: Bioinformatics allows targets. This process accelerates target validation, researchers to stratify patient populations based on 26 27 www.ciolook.com | February 2024 | www.ciolook.com | February 2024 |

molecular profiles, enabling the development of adhere to stringent ethical guidelines to safeguard targeted therapies. Tailoring treatments to specific patient information. genetic or biomarker characteristics enhances efficacy while minimizing adverse effects. Ethical Use of Data: Ethical considerations should guide the collection, storage, and utilization of big data Pharmacogenomics: Understanding how individuals in pharmaceutical research. Transparency, informed respond to drugs based on their genetic makeup is a consent, and adherence to regulatory frameworks are cornerstone of personalized medicine. Bioinformatics essential to maintaining public trust and ethical tools analyze pharmacogenomic data to predict drug standards. responses, optimize dosages, and reduce the risk of adverse reactions. Collaboration and Knowledge Sharing Real-world Evidence and Patient Outcomes Cross-industry Collaborations: The complexity of bioinformatics and big data necessitates collaborative Mining Real-world Data: Big data analytics incorporate efforts. Pharma companies, research institutions, and real-world evidence from electronic health records, technology firms can achieve synergies by sharing data, wearables, and patient-reported outcomes. This wealth expertise, and resources, fostering a collective of data provides insights into treatment effectiveness, approach to advancing research. patient adherence, and long-term outcomes, informing continuous improvements in therapies. Open-access Initiatives: Open-access initiatives promote the sharing of research findings and datasets Evidence-based Decision Making: Pharma researchers within the scientific community. This collaborative can make informed decisions by analyzing real-world ethos accelerates innovation, minimizes duplication of data to understand treatment patterns, identify unmet efforts, and amplifies the impact of discoveries in the needs, and assess the economic impact of field. interventions. This evidence-based approach enhances the value proposition of pharmaceutical innovations. Conclusion Enhancing Clinical Trials and Drug Development The marriage of bioinformatics and big data has unleashed a paradigm shift in pharmaceutical research, Patient Recruitment and Retention: Big data analytics transforming how scientists understand diseases, streamline patient recruitment for clinical trials by discover drugs and personalize treatments. The identifying eligible participants based on specific integration of genomic data, machine learning criteria. Additionally, insights from real-world data algorithms, and real-world evidence has elevated the improve patient retention and trial efficiency, reducing precision and efficiency of drug development. As the costs and expediting the development timeline. industry continues to embrace these technological advancements, the potential for groundbreaking Predictive Analytics in Clinical Trials: Predictive discoveries and improved patient outcomes becomes analytics anticipate potential challenges in clinical increasingly promising. Bioinformatics and big data are trials, helping researchers proactively address issues not just tools; they are catalysts propelling the such as patient dropout rates or adverse events. This pharmaceutical industry into an era of unprecedented foresight enhances trial design and increases the scientific innovation and therapeutic breakthroughs. likelihood of successful outcomes. Ensuring Data Security and Ethical Considerations Data Privacy and Security: As the volume of health- related data grows, ensuring data privacy and security becomes paramount. The pharmaceutical industry must invest in robust cybersecurity measures and 28 www.ciolook.com | February 2024 |

www.ciolook.com

Most Admired Pharma & BioTech Visionaries, Shaping the Industry's Future - 2024

Most Admired Pharma & BioTech Visionaries, Shaping the Industry's Future - 2024

Presentation Transcript